Opus Genetics
IRD
Opus Genetics (IRD) news
Recent news
Opus Genetics Inc: Jonestrading raises target price to $17 from $10
Jonestrading has revised its target price for Opus Genetics Inc (IRD) to $17 from $10, reflecting a 70% increase in its valuation forecast. The adjustment follows a reassessment of the company’s operational performance and market positioning. While the firm’s operations have been described as "too…
AInvest Wire · Oct 6, 2026Opus Genetics - OPGX-Best1 demonstrates favorable safety with no serious adverse events or dose-limiting toxicities
AInvest Wire · Sep 9, 2026Opus Genetics - Cohort 2 dosing to complete in Q4 2026, topline data expected Q2 2027
AInvest Wire · Sep 9, 2026Opus Genetics - FDA aligns on ≥3 decibels microperimetry improvement as potential pivotal endpoint
AInvest Wire · Sep 9, 2026Opus Genetics - All five participants show clinically meaningful improvement in visual function
AInvest Wire · Sep 9, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.